Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

1. Soleno Therapeutics shares dropped 9.68% after a critical report. 2. Vykat XR's high cost and safety concerns could lead to market withdrawal. 3. Multiple hospitalizations have raised serious safety issues regarding Vykat XR. 4. Comparison drawn between Soleno and collapsed Zafgen Inc. suggests potential volatility. 5. The company's focus on a single product raises survival concerns post-2026.